Regencell Bioscience Holdings LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Regencell Bioscience Holdings Limited filed its annual report for fiscal year 2025, revealing continued net losses, negative operating cash flows, and substantial doubt about its ability to continue as a going concern, despite ongoing TCM efficacy trials.
NASDAQ
Regencell Bioscience Holdings Limited files its annual report on Form 20-F, detailing financial results and operational activities for the fiscal year ended June 30, 2024.